POWr Social Media Icons

Sunday, June 14, 2015

Story image for sidama from wsnewspublishersOn Tuesday, Keurig Green Mountain Inc (NASDAQ:GMCR)’s shares declined -0.97% to $84.84.
Keurig Green Mountain Inc (GMCR) launched the Laughing Man branded coffee in K-Cup packs to be brewed exclusively in Keurig hot brewing systems.
The Laughing Man branded K-Cups were made accessible from Jun 4 exclusively on Keurig Green Mountain’s official site — Keurig.com. Laughing Man coffee has offered four varieties, Dukale’s Blend, 184 Duane St. Blend, Ethiopia Sidama and Colombia Huila, for the coffee lovers at the launch. Laughing Man coffee K-Cup pods will come in boxes of 3, 10 and 16-count carrying price tags of $2.49, $9.99 and $12.99, respectively. The company plans to expand the product to retail stores by the end of this year.
n Dec 2014, Keurig Green Mountain reached partnership with New York City-based Laughing Man Worldwide, LLC, to use the Laughing Man Coffee and Tea brands. The Laughing Man Coffee and Tea brand produces gourmet coffees and teas which are distributed across the world.
With the partnership of Keurig Green Mountain and Laughing Man, consumers will be able to enjoy these renowned brands of coffee with the convenience of Keurig brewers.
Keurig Green Mountain, Inc. produces and sells specialty coffee, coffeemakers, teas, and other beverages in the United States and Canada. It sources, produces, and sells coffee, hot cocoa, teas, and other beverages under various brands in K-Cup, Vue, Rivo, K-Carafe, and Bolt portion packs brands; and coffee in traditional packaging, counting bags and fractional packs, in addition to offers whole bean and ground coffee in bags, fractional packages, and cans.
Monsanto Company (NYSE:MON)’s shares dropped -0.33% to $113.54.
Monsanto Company (MON) reaffirmed its commitment to a constructive process to negotiate a mutually beneficial combination as part of the company’s proposal to combine with Syngenta (SYNN.VX) in a cash and stock transaction valued at 449 CHF per share. Monsanto’s proposal would provide Syngenta shareholders with a substantial premium of more than 43 percent over the 314 CHF unaffected share price on April 30, 2015 and a more than 45 percent premium to Syngenta’s 52 week volume weighted average share price, in addition to noteworthy further value creation through ongoing ownership in the combined company. Monsanto has projected to Syngenta a new $2 billion reverse break-up fee payable by Monsanto if it is unable to obtain necessary global regulatory approvals.
Monsanto reiterated that the combined strengths of both companies will accelerate innovation and enhance choice for farmers around the world, unlock improved scale and reach, and provide the opportunity to offer farmers integrated solutions across a broader set of crops, geographies and production practices.
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment produces row crop seeds, counting corn, soybean, cotton, and canola seeds principally under the DEKALB, Channel, Asgrow, and Deltapine brands; and vegetable seeds comprising of tomato, pepper, melon, cucumber, pumpkin, squash, beans, broccoli, onions, lettuce, and other seeds under the Seminis and De Ruiter brands.
At the end of Tuesday’s trade, Globalstar, Inc. (NYSEMKT:GSAT)‘s shares surged 0.87% to $2.32.
Globalstar, Inc. (GSAT) has declared that it has once again teamed up with Lt. General Russel L. Honore, U.S. Army (Stepped down) in an initiative to raise awareness of the irreplaceable role that non-terrestrial based communications, such as Globalstar’s satellite phone solutions, play in emergency and disaster relief situations. In the devastating aftermath of hurricanes Katrina, Rita and more recently, Sandy, satellite communications providers like Globalstar played an essential part in enabling disaster recovery, search and rescue operations and restoring basic services to the public. Lightweight handheld satellite phones and PABX-compatible fixed phone solutions can be rapidly deployed to meet almost any interoperability application involving 2-way radios, telephones, and data networks.
In the aftermath of these recent events, businesses now routinely incorporate satellite phones in their disaster recovery and backup communications planning. Further, as a direct result of Hurricane Katrina, governors have put a renewed focus on statewide disaster preparedness programs, and interoperable emergency communications are a required component of the National Preparedness Aim put forth by the Department of Homeland Security in September 2011. Known for setting the standard in high quality voice and mobile data communications, Globalstar has already been adopted as the preferred statewide backup communications system in many parts of the country.
Globalstar, Inc. provides mobile voice and data communications services through satellite worldwide. The company offers duplex two-way voice and data products, counting mobile voice and data satellite communications services and equipment for remote business continuity, recreational, emergency response, and other applications; fixed voice and data satellite communications services and equipment in rural villages, ships, industrial and commercial sites, and residential sites; and satellite data modem services comprising asynchronous and packet data services.
Advaxis, Inc. (NASDAQ:ADXS), ended its Tuesday’s trading session with -9.68% loss, and closed at $24.34.
Advaxis, Inc. (ADXS) declared that it has designated Fred J. Frullo as Vice President, Regulatory Affairs. With more than 20 years of experience in the biopharmaceutical industry, Mr. Frullo is well versed in the development of global regulatory strategies for the supervision, review and assembly of pharmaceutical product submission and coordination with global health authorities to obtain approvals.
As Vice President, Regulatory Affairs, Mr. Frullo will oversee regulatory submissions for the company’s Lm-LLO cancer immunotherapy clinical programs, counting ADXS-HPV, ADXS-PSA and ADXS-HER2, in addition to combination studies involving complementary immunotherapy technologies. Mr. Frullo will lead the development and submission of all regulatory documents on behalf of Advaxis to the appropriate health agencies and coordinating joint submissions with Advaxis’s planned partners as warranted. In this role, Mr. Frullo will succeed Ms. Chris L. French, MBA, who will now lead the company’s compliance program.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, accomplished its Phase II study.
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.